Are phase I trials safe for older patients?

Area of Science:

• Oncology
• Geriatric Medicine
• Clinical Pharmacology

Background:

• Cancer incidence rises with age, necessitating treatment evaluation in older populations.
• Current Phase I oncology trials often exclude older patients, with varied age thresholds (65-80 years).
• Limited data exists on the safety and efficacy of Phase I trials specifically in elderly individuals.

Purpose of the Study:

• To review and analyze published data on Phase I oncology trials involving older patients.
• To assess the safety and efficacy profiles of new anti-cancer drugs in geriatric populations.
• To evaluate the feasibility of including older adults in early-phase oncology drug development.

Main Methods:

• Systematic review of published Phase I clinical trial data.
• Analysis focused on patient demographics, particularly age inclusion criteria.
• Examination of reported toxicity and efficacy outcomes in relation to patient age.

Main Results:

• Most reviewed studies predominantly enrolled younger, healthier patients.
• Patient age did not correlate with increased drug toxicity.
• Efficacy outcomes were not negatively impacted by older patient age.

Conclusions:

• Phase I oncology trials are feasible in fit older patients.
• Age alone should not be a primary exclusion criterion.
• Incorporating geriatric assessment tools is recommended for better patient characterization in trial design.